Details

Autor(en) / Beteiligte

• Heymer, Emma J
• Hawkins, Michael M
• Winter, David L
• Teepen, Jop C
• Sunguc, Ceren
• Ronckers, Cécile M
• Allodji, Rodrigue S
• Alessi, Daniela
• Sugden, Elaine
• Belle, Fabiën N
• Bagnasco, Francesca
• Byrne, Julianne
• Bárdi, Edit
• Garwicz, Stanislaw
• Grabow, Desiree
• Jankovic, Momcilo
• Kaatsch, Peter
• Kaiser, Melanie
• Michel, Gisela
• Schindera, Christina
• Haddy, Nadia
• Journy, Neige
• Česen Mazić, Maja
• Skinner, Roderick
• Kok, Judith L
• Gunnes, Maria W
• Wiebe, Thomas
• Sacerdote, Carlotta
• Maule, Milena M
• Terenziani, Monica
• Jakab, Zsuzsanna
• Winther, Jeanette F
• Lähteenmäki, Päivi M
• Zadravec Zaletel, Lorna
• Haupt, Riccardo
• Kuehni, Claudia E
• Kremer, Leontien C
• de Vathaire, Florent
• Hjorth, Lars
• Reulen, Raoul C

Titel

Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study

Ist Teil von

• British journal of cancer, 2024-04, Vol.130 (6), p.976-986

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2024

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Childhood cancer survivors are at risk of subsequent gliomas and meningiomas, but the risks beyond age 40 years are uncertain. We quantified these risks in the largest ever cohort. Using data from 69,460 5-year childhood cancer survivors (diagnosed 1940-2008), across Europe, standardized incidence ratios (SIRs) and cumulative incidence were calculated. In total, 279 glioma and 761 meningioma were identified. CNS tumour (SIR: 16.2, 95% CI: 13.7, 19.2) and leukaemia (SIR: 11.2, 95% CI: 8.8, 14.2) survivors were at greatest risk of glioma. The SIR for CNS tumour survivors was still 4.3-fold after age 50 (95% CI: 1.9, 9.6), and for leukaemia survivors still 10.2-fold after age 40 (95% CI: 4.9, 21.4). Following cranial radiotherapy (CRT), the cumulative incidence of a glioma in CNS tumour survivors was 2.7%, 3.7% and 5.0% by ages 40, 50 and 60, respectively, whilst for leukaemia this was 1.2% and 1.7% by ages 40 and 50. The cumulative incidence of a meningioma after CRT in CNS tumour survivors doubled from 5.9% to 12.5% between ages 40 and 60, and in leukaemia survivors increased from 5.8% to 10.2% between ages 40 and 50. Clinicians following up survivors should be aware that the substantial risks of meningioma and glioma following CRT are sustained beyond age 40 and be vigilant for symptoms.